<DOC>
	<DOCNO>NCT01587313</DOCNO>
	<brief_summary>This single center , open-label , two-period study . There nine healthy human volunteer arbitrarily assign one four group . The study objective compare action various combination BiDil extended-release capsule commercial BiDil Tablets body period time .</brief_summary>
	<brief_title>A Comparison Various Combinations BiDil Capsules BiDil Tablets Healthy Human Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Healthy , nonsmoking , slow acetylator ( determined caffeine metabolite assay ) male female age 18 40 year inclusive . Body weight least 150 pound Body Mass Index 18.5 30 kg/m2 . Medical history , physical examination , clinical laboratory test result indicate either normal vital organ/endocrine function , clinically significant abnormality . Clinical laboratory test negative : HIV , Hepatitis B surface antigen Hepatitis C antibody . Urine test negative drug abuse ( include , limited marijuana , amphetamine , barbiturate cocaine ) . Negative urine cotinine test negative saliva alcohol test . Negative urine HCG test , consistent pregnancy ( female ) . For female subject , recent history menses regular individual ( 24 36 day cycle ) . Females participate study must : unable child ( e.g. , postmenopausal , tubal ligation , hysterectomy ) OR willing remain abstinent [ engage sexual intercourse duration screen period throughout study , 14 day last dose ] OR willing use two effective barrier method birth control ( partner use condom female use IUD , diaphragm plus spermicide , contraceptive sponge ) . Ability grant voluntary inform consent participate study . Known history presence clinically significant medical condition . Known suspected carcinoma . Use prescription OTC drug ( ) , acetaminophen , within two week first dose study drug throughout study unless approve investigator sponsor . Use alcohol caffeine containing product within 48 hour dose study drug . History , evidence clinically significant medical condition , include , limited hepatic , renal , cardiac , vascular , gastrointestinal , thyroid disease , diabetes , epilepsy , respiratory hematological disease , acute narrow angle glaucoma psychiatric disorder , opinion Investigator would confound study result present risk subject . History alcohol drug abuse within one year study participation . Presence , know hypersensitivity , allergy , idiosyncratic reaction adverse reaction caffeine , ISDN , hydralazine HCl , compound similar chemical characteristic . Received investigational drug within 30 day first dose study . Blood pressure le 110/70 mm Hg screen Day 1 prior dose . Donated one pint blood donate platelet within 30 day first dose study . Any subject , opinion Investigator , follow instruction . With regard female ; pregnancy , lactation , use hormonal contraception . History lupus erythematous lupus like syndrome . Use herbal preparation use phosphodiesterase inhibitor . Employee Sponsor CRO .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>hydralazine</keyword>
	<keyword>isosorbide</keyword>
	<keyword>bidil</keyword>
	<keyword>volunteer</keyword>
	<keyword>pharmacokinetic profile</keyword>
</DOC>